Live Webinar

Thursday, June 18th | 5:00 PM CST

Histotripsy at Vanderbilt: Clinical Implementation & Advanced Research at an Academic Center

Join us for a dynamic discussion on launching a histotripsy program, patient selection, and operational impact.

Speakers: Sekhar Padmanabhan, MD, Surgical Oncologist, Vanderbilt Health and Joe Herman, MD, Medical Director, HistoSonics and Adjunct Professor at Zucker School of Medicine at Hofstra/Northwell

Secure your spot! Register here.

Let’s Get Started

Please register to attend a personalized Edison demonstration.

This field is for validation purposes and should be left unchanged.

Name(Required)

First Last

Email(Required)

Facility Location(Required)

Program of Interest(Required)

Turnstile

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

The is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics Inc., and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

Footer last updated on June 30, 2025